Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Neoplasm
86%
Clinical Trial
82%
Advanced Cancer
81%
Diseases
80%
Malignant Neoplasm
76%
Adverse Event
40%
Bevacizumab
36%
Overall Survival
36%
Progression Free Survival
33%
Phase I Trials
32%
Paclitaxel
32%
Maximum Tolerated Dose
25%
Ovary Cancer
25%
Pharmacokinetic
23%
Antitumor Activity
22%
Colorectal Carcinoma
21%
Epidermal Growth Factor Receptor
20%
Carboplatin
20%
Chemotherapy
19%
Oxaliplatin
17%
Vasculotropin
16%
Breast Cancer
15%
Immunotherapy
15%
Selinexor
15%
Thrombocytopenia
15%
Melanoma
14%
Pembrolizumab
13%
Mammalian Target of Rapamycin Inhibitor
13%
Temsirolimus
13%
Combination Therapy
13%
Non Small Cell Lung Cancer
13%
Cetuximab
12%
Adavosertib
12%
Diarrhea
12%
Metastasis
11%
Tolerability
11%
Erlotinib
10%
Rash
10%
Ovary Carcinoma
10%
Liver Metastasis
10%
Phosphotransferase Inhibitor
10%
Connective Tissue Cancer
10%
Uterine Cervix Cancer
10%
Pazopanib
9%
Lenalidomide
9%
Sodium Valproate
9%
Fluorouracil
8%
Biological Marker
8%
Female Genital Tract Cancer
8%
Keyphrases
Patients with Advanced Cancer
66%
Stable Disease
54%
Advanced Solid Tumors
52%
Phase I Study
44%
Partial Response
43%
Phase I Clinical Trial
37%
Bevacizumab
36%
Phase I Trial
34%
MD Anderson Cancer Center
31%
Dose-limiting Toxicity
25%
Paclitaxel
23%
Tumor
22%
Maximum Tolerated Dose
22%
PIK3CA mutation
21%
Confidence Interval
21%
Non-small Cell Lung Cancer (NSCLC)
20%
Early Phase Clinical Trials
20%
Antitumor Activity
19%
Targeted Therapy
19%
Overall Survival
19%
Pembrolizumab
18%
Mammalian Target of Rapamycin (mTOR)
17%
Advanced Cancer
17%
MTOR Inhibitor
17%
Ovarian Cancer
16%
Solid Tumors
16%
Tumor Subtype
16%
Carboplatin
15%
Dose Escalation
15%
Median Progression-free Survival
15%
Progression-free Survival
15%
Selinexor
15%
Adverse Events
15%
Treatment-related Adverse Events
14%
Clinical Trials
14%
Cetuximab
14%
Hepatic Arterial Infusion
14%
KRAS mutation
13%
Dose Level
13%
Chemotherapy
13%
Objective Response Rate
13%
Temsirolimus
13%
Median Overall Survival
13%
Advanced Malignancies
12%
Dose-escalation Study
12%
Clinical Benefit
12%
Clinical Outcomes
12%
PIK3CA
12%
Colorectal Cancer
11%
Dose Expansion
11%
Medicine and Dentistry
Clinical Trial
66%
Neoplasm
61%
Advanced Cancer
53%
Cancer
49%
Malignant Neoplasm
49%
Diseases
42%
Overall Survival
30%
Progression Free Survival
28%
Solid Malignant Neoplasm
27%
Targeted Therapy
26%
Ovarian Cancer
22%
Immunotherapy
18%
Colorectal Carcinoma
17%
Pembrolizumab
15%
Phase I Trials
15%
Metastatic Carcinoma
14%
Adverse Event
13%
Mammalian Target of Rapamycin Inhibitor
11%
Krukenberg Tumor
11%
Epidermal Growth Factor Receptor
11%
Connective Tissue Cancer
11%
Antineoplastic Activity
10%
Bevacizumab
10%
Next Generation Sequencing
10%
Mammalian Target of Rapamycin
10%
Melanoma
9%
Non Small Cell Lung Cancer
9%
PI3K/AKT/mTOR Pathway
9%
Carboplatin
8%
Systemic Therapy
8%
Hazard Ratio
8%
Cancer Therapy
8%
Personalized Medicine
8%
Oxaliplatin
8%
Cell-Free DNA
7%
Prevalence
7%
Cancer Cell
7%
Paclitaxel
7%
Hepatic Arterial Infusion
7%
Immune Checkpoint Inhibitor
7%
Breast Cancer
7%
Adavosertib
7%
Vasculotropin
7%
Multivariate Analysis
7%
Arm
7%
Oncology
6%
Cervical Cancer
6%
Lung Cancer
6%
Combination Therapy
6%
Vorinostat
6%